Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.

1 Jan 2012

Abstract excerpt

Radiotherapy plays a central part in cancer treatment, and use of radiosensitizing agents can greatly enhance this modality. Although studies have shown that several chemotherapeutic agents have the potential to increase the radiosensitivity of tumor cells, investigators have also studied a number of molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising preclinical data....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to DNA Repair Mechanisms
Share to Radiation Therapy and Dosimetry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22525466
DOI: 10.18926/amo/48258

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.PMID 22525466Read ↗

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancerSemantic proximity Read ↗

Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell deathSemantic proximity Read ↗

Molecular targets that sensitize cancer to radiation killing: From the bench to the bedsideSemantic proximity Read ↗

MRE11 as a molecular signature and therapeutic target for cancer treatment with radiotherapySemantic proximity Read ↗

Molecular basis of ataxia telangiectasia and related diseases.Semantic proximity Read ↗

Targeting Rad50 sensitizes human nasopharyngeal carcinoma cells to radiotherapy.Semantic proximity Read ↗

Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy.Semantic proximity Read ↗

MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatmentSemantic proximity Read ↗

Dual role of Nbs1 in the ataxia telangiectasia mutated-dependent DNA damage response.Semantic proximity Read ↗

Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of RadiosensitizationSemantic proximity Read ↗

Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapySemantic proximity Read ↗

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage ResponsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.